| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, U.K.—Cardiac complications and side effects have traditionally been one of the major areas that cause otherwise promising therapeutic candidates to fail late in the drug development process, so anticipating and heading off this problem at the discovery and preclinical stages is crucial.
 
Cresset Discovery Services, a provider of contract research services for early-phase discovery, and Inocardia, a provider of cardiac safety testing models, have announced a one-year collaboration to develop improved computational methods for cardiac safety assessment. This collaboration also includes the University of Coventry and UCB, and is supported by EIT Digital.
 
The collaboration builds on a successful 2019 proof-of-concept project. In this new phase Cresset Discovery Services and its project partners will utilise ligand-based similarity methods in Forge, docking and Electrostatic Complementarity in Flare and chemical space analysis to model key biological modes of action. The models will be used to predict biological response.
 
“This exciting collaboration will produce valuable and useful work,” said Dr. Robert Scoffin, Cresset’s CEO. “In-silico predictions are increasingly being used alongside time-consuming or expensive wet biological assays to create a fuller picture of the pharmacological landscape.”
 
“Drug-induced cardiac contractility issues are often identified too late in R&D campaigns,” added Dr. Jeremy Billson, CEO at Inocardia. “Our novel assays improve early detection of cardiac safety issues and we are looking forward to extending this further using computational methods to help pharmacologists avoid expensive downstream problems.”

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue